{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.134"}]}],"title":"Ka1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55"}]}],"title":"Ka2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"}],"units":"Participants"}],"description":"The population pharmacokinetic (PopPK) model of trametinib can be described using a two-compartment model with dual sequential 1st order absorption (Ka1, Ka2) and 1st order elimination. The absorption rate constants (Ka1 and Ka2) estimated with the PopPK model are summarized in this record.","groups":[{"description":"Participants in the study (all doses and all tumor types) with available pharmacokinetic data","id":"OG000","title":"Part A, B, C and D - All Participants With PK Data"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least one dose of trametinib in Part A, B, C and D and provided an evaluable PK profile. All trametinib and dabrafenib concentration-time data were combined and included in a population PK analysis that examined the influence of demographics on the PK of study treatment.","reportingStatus":"POSTED","timeFrame":"pre dose, 1, 2, 4, 7, 10 and 24 hours post trametinib dose on Cycle 1 Day 15 (part A and B) and pre dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post trametinib dose on Cycle 1 Day 15 (part C and D). The duration of 1 cycle was 28 days.","title":"Absorption Rate Constants (Ka1 and Ka2) of Trametinib Estimated With a PopPK Model","type":"SECONDARY","unitOfMeasure":"1/hours"}